SaNOtize Research & Development Corp.: Newly Published Phase 3 Study in People with COVID-19 Shows SaNOtize Nitric Oxide Nasal Spray Reduced Viral Load by 99% within Two Days

Phase 3 trial demonstrated a reduction in SARS-CoV-2 viral load in high-risk COVID-19 patients by 94% and 99% within 24 and 48 hours of treatment, respectively Median time to a negative PCR

Related Keywords

Canada ,Thailand ,India ,Hong Kong ,United Kingdom ,Israel ,Singapore ,Nepal ,Vancouver ,British Columbia ,Indonesia ,Bahrain ,Canadian ,Chris Miller ,Kostenloser Wertpapierhandel ,Sean Gjos ,Gilly Regev ,Sanotize Co ,Thelancet Regional Health Southeast Asia ,Linkedin ,Twitter ,Sanotize Research Development Corp ,European Union ,India Central Drugs Standard Control Organization ,Glenmark Pharmaceuticals Limited ,Business Development ,Research Development Corp ,Progression Scale ,Chief Scientific Officer ,Central Drugs Standard Control Organization ,Research Development ,Nitric Oxide Releasing Solution ,Media Contact ,Sanotize ,Research ,Development ,Orp ,Ewly ,Published ,Hase ,Study ,People ,Covid ,Shows ,Mitric ,Xide ,Nasal ,Spray ,Educed ,Viral ,Road ,Ithin ,Ways ,